The size of the Global Generic Drugs Market was worth USD 290.83 billion in 2019 and is expected to reach USD 412.50 billion by 2024, growing at a CAGR of 7.24% during the forecast period 2019 - 2024.
The increase in the incidence of chronic diseases is a significant driver of the global generic drugs market. The cost increase in existing medicines is also the factor that is responsible for Global Generic Drugs Market growth. The cost-effective and availability of drugs is driving business growth. The popularity of chronic diseases and existing markets drive the generic drugs market growth.
The lack of having knowledge about the generic drug market is the curb to the worldwide market. In developing countries, drugs are cheap, but the quality is restraining growth.
Emerging markets like India and China are supposed to generate more opportunities for the generic drugs market.
High competition and shortage of drugs are restraining the Global Generic Drugs Market. Prescription of doctors is affecting the growth because the doctors are prescribing branded drugs/medicines to the patients. Biosimilar developers focus on proteins of highly complicated, high cost and even more world experience of manufacturing, which will be challenging to follow existing processes for proving a high degree of similarity.
Market Size Available
2018 – 2024
2019 – 2024
By Type, Application, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others
This research report on the Global Generic Drugs Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
Generic Drugs Market Analysis - By Type:
Generic Drugs Market Analysis - By Application:
North America held the most substantial share value in the Global Generic Drugs Market during the forecast period. This is mainly due to the prescription patterns that are mostly covered with branded generic drugs. Hence, the demand for the market is high in this region. Europe is anticipated to have a significant growth which is due to an increase in the commonness of chronic diseases and government support for the generic drug market.
Nations like India and China in the Asia-Pacific region dominated the global generic drugs business in terms of volume. India is leading in this region due to the number of Indian companies waiting for approval in the U.S and other countries.
In Latin America, Brazil was the largest generic drug market due to the sale of the drugs, which is leading in the biopharmaceutical sector by value and by volume. This nation is foreseen to remain in power and influence in this region, owing to high demand and a rise in development in the pharmaceutical sector.
List of key market participants leading the Global Generic Drugs Market profiled in the report are:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.3 simple generics
5.1.4 Super generics
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Therapeutic drugs
5.2.2 Cardiovascular Products
5.2.3 Anti-infective Drugs
5.2.4 Anti Arthritis Drugs
5.2.5 Central Nervous System Drugs
5.2.6 Anti Cancer Drugs
5.2.7 Respiratory System Drugs
5.2.9 Y-o-Y Growth Analysis, By Therapeutic Drugs
5.2.10 Market Attractiveness Analysis, By Therapeutic Drugs
5.2.11 Market Share Analysis, By Therapeutic Drugs
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Type
188.8.131.52 By Therapeutic Drugs
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Type
18.104.22.168 By Therapeutic Drugs
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By type
188.8.131.52 By Therapeutic Drugs
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Ranbaxy Laboratories
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.3 Mylan, Inc. Industries, Ltd.
8.4 Dr. Reddy’s Laboratories
8.5 Par Pharmaceutical, Inc.
8.6 Sandoz International GmbH
8.7 Celgene Corporation
8.8 Apotex, Inc.
8.9 Watson Pharmaceuticals, Ltd.
8.10 Teva Pharmaceutical and others.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures